Disease areas:
  • eye
Last updated:
Author(s):
Aaron M Holleman, Aimee M Deaton, Rachel A Hoffing, Lynne Krohn, Philip LoGerfo, Paul Nioi, Mollie E Plekan, Sebastian Akle Serrano, Simina Ticau, Tony E Walshe, Anna Borodovsky, Lucas D Ward
Publish date:
17 April 2025
Journal:
American Journal of Human Genetics
PubMed ID:
40250423

Abstract

Age-related macular degeneration (AMD) is a leading cause of blindness among older adults worldwide, but treatment options are limited. Genetics studies have implicated the CFH locus, containing CFH and five CFHR genes, CFHR1-5, in AMD. While CFH has been robustly linked with AMD risk, potential additional roles for the CFHR genes remain unclear, obscured by strong linkage disequilibrium across the locus. Investigating rare coding variants can help to identify causal genes in such regions. We used whole-exome sequencing data from 406,952 UK Biobank participants to examine AMD associations with genes at the CFH locus. For each gene, we used burden testing to examine associations of rare (minor-allele frequency [MAF] < 1%) predicted loss-of-function (pLoF) and predicted damaging missense variants with AMD. We considered “broadly defined AMD” (ICD-10 35.3; ncases = 10,700) and “strictly defined AMD” (dry or wet AMD; ncases = 346). Adjusting for CFH-region variants known to independently associate with AMD, we find that CFHR5 rare variant burden significantly associates with a decreased risk of broadly defined AMD (odds ratio [OR] = 0.75, p = 7 × 10-4), with this association primarily driven by pLoF variants. Furthermore, the association of CFHR5 rare variants with AMD protection is estimated to be stronger for individuals with the CFH rs1061170 AMD risk allele (p.Tyr402His [p.Y402H]; interaction p = 0.04). Corresponding analyses of strict AMD were underpowered. However, we observe that thinning of the photoreceptor layer outer segment strongly predicts strict AMD and find that CFHR5 rare variant burden is significantly associated with increased thickness of this retinal layer (+0.34 SD, p = 4 × 10-4, n = 45,365). These findings suggest CFHR5 inhibition as a potential therapeutic approach for AMD.

Related projects

1. The primary scientific goal of the research is to apply human genetics to the identification of new drug targets, the validation of existing targets…

Institution:
Regeneron Genetics Center, LLC, United States of America

The primary scientific goal of this research project is to apply multiplex proteomic profiling of 56,000 UK Biobank plasma samples to facilitate the identification of…

Institution:
Pfizer Inc, USA, United States of America

All projects